- Report
- March 2024
- 186 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Drug Pipelines
- April 2024
- 120 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- September 2021
- 40 Pages
China
From €2510EUR$2,600USD£2,153GBP
- Report
- January 2019
- 212 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- February 2024
- 180 Pages
Global
From €3475EUR$3,600USD£2,981GBP
Risedronate is a medication used to treat and prevent osteoporosis, a condition characterized by weak and brittle bones. It belongs to a class of drugs known as bisphosphonates, which work by slowing down the rate of bone breakdown and increasing bone density. Risedronate is also used to treat Paget's disease of bone, a disorder that causes abnormal bone growth and pain. It is available in both oral and intravenous forms.
Risedronate is a widely used drug in the Endocrine and Metabolic Disorders Drugs market. It is used to treat and prevent osteoporosis, a condition that affects millions of people worldwide. It is also used to treat Paget's disease of bone, a rare disorder that causes abnormal bone growth and pain. Risedronate is generally well-tolerated and has few side effects.
Some companies in the Risedronate market include Merck & Co., Inc., Teva Pharmaceuticals, and Mylan N.V. These companies manufacture and distribute the drug in various forms, including tablets, capsules, and injections. Show Less Read more